Navigation Links
Anadys Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Date:10/14/2010

tate or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C.  Anadys believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines.  Anadys is developing ANA598, a direct-acting antiviral or DAA, for the treatment of hepatitis C. In an ongoing Phase II study, Anadys has completed 12 weeks of dosing ANA598 added to current standard of care. Anadys has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' expectations regarding its proposed public offering, Anadys' expected use of proceeds from the offering, Anadys' development programs including the anticipated timing for commencement of its Phase IIb study of ANA598, and Anadys' ability to develop novel medicines in the area of hepatitis C. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, there are risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering. In addition, the results of preclinical and early clinical studies
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Mass. , Nov. 25, 2014 Reinforcing ... Royal Philips (NYSE: PHG AEX: ... and Drug Administration (FDA) for its IQon Spectral ... imaging. This first-of-its kind technology adds a new dimension ... offering the ability to characterize structures based on their ...
(Date:11/26/2014)... , Nov. 25, 2014  Array BioPharma ... announced that its Chief Executive Officer, ... following upcoming conferences.  The public is welcome ... on the Array BioPharma website:  www.arraybiopharma.com ... 2014Time:1:30 p.m.  Eastern Time Location: Palace Hotel, ...
(Date:11/26/2014)... Nov. 25, 2014 Halozyme Therapeutics, Inc. (NASDAQ: ... Healthcare Conference in New York on ... . Dr. Helen Torley , President and Chief ... presentation will be webcast through the "Investors" section of Halozyme,s ... be made available for 90 days following the event. To ...
Breaking Medicine Technology:Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
... Feb. 23, 2012  BioSpecifics Technologies Corp. (NASDAQ: ... in class collagenase-based products marketed as XIAFLEX® in ... today announced that its partner Auxilium Pharmaceuticals, Inc. ... Pharmaceuticals Ltd. (Actelion) for the long-term development, supply ...
... Feb. 23, 2012 Idenix Pharmaceuticals, Inc. (NASDAQ: ... discovery and development of drugs for the treatment of ... the fourth quarter and year ended December 31, 2011 ... virus (HCV) development pipeline. Operational ...
Cached Medicine Technology:BioSpecifics Announces Partnership Between Auxilium and Actelion for XIAFLEX® in Canada, Australia, Brazil and Mexico 2BioSpecifics Announces Partnership Between Auxilium and Actelion for XIAFLEX® in Canada, Australia, Brazil and Mexico 3BioSpecifics Announces Partnership Between Auxilium and Actelion for XIAFLEX® in Canada, Australia, Brazil and Mexico 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 3Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 5Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 6Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 7Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 8
(Date:11/26/2014)... Sonoran Vein and Endovascular nurse, Jennifer E. ... Award from The American Association of Nurse ... of nurse practitioners. The Distinguished Preceptorship Award recognizes ... a significant contribution toward increasing the awareness and ... Practitioners (AANP) is the largest full-service national professional ...
(Date:11/26/2014)... 25, 2014 (HealthDay News) -- Vultures have developed highly ... ingest when eating dead animals, researchers report. The ... on the faces and in the guts of 50 ... On average, the faces of the vultures had more ... in their guts, the study found. The findings ...
(Date:11/26/2014)... Exposure to peanut protein in household dust may increase ... skin condition eczema, a new study reveals. About ... are allergic to peanuts. And severe eczema in infants ... the researchers noted. The new study included 359 ... examined the amount of peanut protein the children were ...
(Date:11/26/2014)... 2014 (HealthDay News) -- Parents need to take an ... an expert warns. Parents must make sure sports-playing ... Dr. David Dodick, chair of the American Migraine Foundation ... College of Medicine in Scottsdale, Ariz. in an American ... Any coach involved with teens sports needs to ...
(Date:11/24/2014)... Los Angeles, CA (PRWEB) November 24, 2014 ... to bringing its readers reviews of affordable skin care ... , the casual blog offers readers a wide variety ... the market as well as organic skincare alternatives. , ... Healthy Skin Care Journal’s main content includes thoroughly researched ...
Breaking Medicine News(10 mins):Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:Infants With Eczema May Be More Prone to Peanut Allergy: Study 2Health News:Parents Need to Take Lead on Teen Concussion Prevention 2Health News:Skin Care Advice Blog The Healthy Skin Care Journal Now Accessible to the Public 2
... a bacteria resistant to certain antibiotics. This bacteria occurs ... especially in hospitals and nursing homes and is known ... the Netherlands, Sweden, and Norway, where MRSA has been ... facing an increase in incidence with the rates starting ...
... – 'In Zambia, people in the tourist resort city of ... dead chickens at the owners backyards'. // ,Simon ... confirmed evidences were found after thorough investigation of the outbreak'. ... not been cleared yet but residents who cooked and ate ...
... future for those suffering with the deadly disease of Hepatitis C ... that he would speak with the government for the introduction of ... these diseases while administering blood and blood products. ,This ... , These people suffer from the problem of not ...
... Yale university researchers it was found that forced out of work ... rate of heart attacks //. They analyzed about 4,301 people between ... the study were published in the Occupational and Environmental Medicine journal. ... in about 10 years time period as they were forced out ...
... After the vocal demonstrations in hospitals against reservation policy ... face//. This time it is by the staff ... The bone of contention is the incident wherein some ... administration now is taking steps to check overcrowding of ...
... the Wake Forest University School of Medicine and colleagues ... difficult medical procedures //about the dizzy feel of nausea ... strongly affect how they respond to adversity – both ... Ph.D. ‘Being prepared for difficulty can benefit people greatly.’ ...
Cached Medicine News:Health News:Super-bug MRSA Getting Fitter And Out of Control 2Health News:Precautious Measure Help Tolerate Nausea In Patients 2Health News:Precautious Measure Help Tolerate Nausea In Patients 3
...
Medtronic neurosurgery external drainage and monitoring (EDM) products meet a variety of needs for CSF drainage and monitoring....
Lumbar External Drainage System (LED) with Touhy needle is indicated for temporary access to the Lumbar Subarachnoid region as a means of draining cerebral spinal fluid (CSF) in order to reduce incre...
Monitorr ICP external CSF drainage system with self-contained ICP setting....
Medicine Products: